MaxCyte Latest News

MaxCyte marks over a quarter-century remaining steadfast in its mission to provide the life sciences community with the necessary technologies, as well as scientific, technical and regulatory support, to develop biomedical innovations that will transform human health.

New collaboration aims to improve patient outcomes and boost biopharma workforce development.

Cynthia Collins joins the board with extensive and impressive leadership experience in the fields of cell therapy and genetic medicine that will be invaluable to MaxCyte in the coming years.

Ali Soleymannezhad will lead MaxCyte’s commercial operations to increase adoption of the ExPERT Platform, provide best-in-class scientific, technical and regulatory support to customers, and expand the company’s market impact in cell and gene therapy.

In the last three months, Kamau Therapeutics became a strategic platform licensee partner, Porton Advance adopted the ExPERT GTx Flow Electroporation as part of their offerings, and ScaleReady and MaxCyte have collaborated on the G-Rex Grant Program to support cell and gene therapy advancements.

Marina Prasek is a project and portfolio management leader with demonstrated success in new product development and commercialization that joined MaxCyte in January of 2024.

MaxCyte and Kamau Therapeutics, a clinical-stage stem cell therapy gene correction company, announce they are entering into a strategic platform license (SPL) agreement.

MaxCyte’s electroporation expertise and equipment are available to all G-Rex grant recipients through an exclusive offer, including a discounted instrument, one pack of non-GMP processing assemblies and an ExPERT Platform Starter Pack.

James Brady, PhD, Senior Vice President at MaxCyte, highlights the risks of using viral vectors in cell and gene therapy (CGT) and provides electroporation as an alternative capable of reducing safety concerns, greater payload flexibility, and reduced production complexities.

Porton Advanced recently introduced the MaxCyte ExPERT GTx instrument to their cell therapy platform, marking the company as the first cell therapy CDMO in China to possess this clinical-grade Flow Electroporation system.